Alle Storys
Folgen
Keine Story von Sartorius AG mehr verpassen.

Sartorius AG

euro adhoc: Sartorius AG
Nine-month earnings for 2004 already above full-year earnings for 2003
Group sales revenue and order intake significantly up from the previous year’s level
Debt further reduced
Full-year targets unchanged

Disclosure announcement transmitted by euro adhoc.
  The issuer is responsible for the content of this announcement.
In the first nine-month period of 2004, the Sartorius Group increased
its sales revenue by 3.9% (currency-adjusted: 6.6%) to €337.5 million
from €324.8 million a year ago. We raised sales revenue of the
Biotechnology Division by 2.9% (currency-adjusted:  5.7%) to €170.8
million (previous year:  €166.1 million), and that of the
Mechatronics Division by 5.0% (currency-adjusted: 7.4%) to €166.6
million (previous year: €158.7 million).
Concerning order intake, we posted a substantial increase of 9.1%
(currency-adjusted: 12.3%) to €347.6 million (previous year:  €318.6
million). For the Biotechnology Division, order intake rose 10.1%
(currency-adjusted: 13.8%); for the Mechatronics Division, order
intake climbed 8.1% (currency-adjusted: 10.7%).
We boosted EBITDA in the first nine-month period of 2004 to €36.6
million from €16.6 million a year ago and improved EBIT to €20.3
million (previous year:  - €0.7 million). We raised EBIT for the
Biotechnology Division to €10.2 million (previous year:  €0.7
million); and increased that for the Mechatronics Division to €10.1
million (previous year: - €1.5 million).
We primarily used net cash flow of €21.8 million (previous year: 
€26.6 million) to reduce our net debt to €92.1 million (reporting
date on December 31, 2003: €105.0 million).
We continue to adhere to our full-year targets for increasing sales
revenue in the mid- to upper percentage range of one digit and for
doubling EBIT.
end of announcement                    euro adhoc 28.10.2004 08:00:00 

Further inquiry note:

Heiko Imöhl
Vice President
Treasury & Investor Relations
phone : +49 551 308 4034

Branche: Biotechnology
ISIN: DE0007165607
WKN: 716560
Index: Prime Standard, CDAX, Prime All Share, Technologie All Share
Börsen: Berliner Wertpapierbörse / free trade
Hamburger Wertpapierbörse / free trade
Baden-Württembergische Wertpapierbörse / free trade
Börse Düsseldorf / free trade
Bayerische Börse / free trade
Bremer Wertpapierbörse (BWB) / free trade
Frankfurter Wertpapierbörse / official dealing
Niedersächsische Börse zu Hannover / official dealing

Weitere Storys: Sartorius AG
Weitere Storys: Sartorius AG